|
1
|
Lang BH, Wong KP, Cheung CY, Wan KY and Lo
CY: Evaluating the prognostic factors associated with
cancer-specific survival of differentiated thyroid carcinoma
presenting with distant metastasis. Ann Surg Oncol. 20:1329–1335.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin JD, Huang MJ, Juang JH, et al: Factors
related to the survival of papillary and follicular thyroid
carcinoma patients with distant metastases. Thyroid. 9:1227–1235.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sabra MM, Dominguez JM, Grewal RK, et al:
Clinical outcomes and molecular profile of differentiated thyroid
cancers with radioiodine-avid distant metastases. J Clin Endocrinol
Metab. 98:E829–E836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Droz JP, Schlumberger M, Rougier P, Ghosn
M, Gardet P and Parmentier C: Chemotherapy in metastatic
nonanaplastic thyroid cancer: experience at the Institut
Gustave-Roussy. Tumori. 76:480–483. 1990.PubMed/NCBI
|
|
5
|
Schlumberger M: Target therapies for
radioiodine refractory advanced thyroid tumors. J Endocrinol
Invest. 35:40–44. 2012.PubMed/NCBI
|
|
6
|
Salvatore G, De Falco V, Salerno P, et al:
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin
Cancer Res. 12:1623–1629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M: BRAF mutation in papillary thyroid
cancer: pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu D, Hu S, Hou P, Jiang D, Condouris S
and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores
expression of iodide-metabolizing genes in thyroid cells expressing
the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lito P, Rosen N and Solit DB: Tumor
adaptation and resistance to RAF inhibitors. Nat Med. 19:1401–1409.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Montero-Conde C, Ruiz-Llorente S,
Dominguez JM, et al: Relief of feedback inhibition of HER3
transcription by RAF and MEK inhibitors attenuates their antitumor
effects in BRAF-mutant thyroid carcinomas. Cancer Discov.
3:520–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haigis MC and Guarente LP: Mammalian
sirtuins - emerging roles in physiology, aging, and calorie
restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo J, Nikolaev AY, Imai S, et al:
Negative control of p53 by Sir2alpha promotes cell survival under
stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Westerheide SD, Anckar J, Stevens SM Jr,
Sistonen L and Morimoto RI: Stress-inducible regulation of heat
shock factor 1 by the deacetylase SIRT1. Science. 323:1063–1066.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodgers JT, Lerin C, Haas W, Gygi SP,
Spiegelman BM and Puigserver P: Nutrient control of glucose
homeostasis through a complex of PGC-1alpha and SIRT1. Nature.
434:113–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodgers JT, Lerin C, Gerhart-Hines Z and
Puigserver P: Metabolic adaptations through the PGC-1 alpha and
SIRT1 pathways. FEBS Lett. 582:46–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brunet A, Sweeney LB, Sturgill JF, et al:
Stress-dependent regulation of FOXO transcription factors by the
SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brachmann CB, Sherman JM, Devine SE,
Cameron EE, Pillus L and Boeke JD: The SIR2 gene family, conserved
from bacteria to humans, functions in silencing, cell cycle
progression, and chromosome stability. Genes Dev. 9:2888–2902.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bishop NA and Guarente L: Genetic links
between diet and lifespan: shared mechanisms from yeast to humans.
Nat Rev Genet. 8:835–844. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raynes R, Brunquell J and Westerheide SD:
Stress inducibility of SIRT1 and its role in cytoprotection and
cancer. Genes Cancer. 4:172–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Verdin E: AROuSing SIRT1: identification
of a novel endogenous SIRT1 activator. Mol Cell. 28:354–356. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorospe M and de Cabo R: AsSIRTing the DNA
damage response. Trends Cell Biol. 18:77–83. 2008. View Article : Google Scholar
|
|
22
|
Brennan CM and Steitz JA: HuR and mRNA
stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lopez de Silanes I, Zhan M, Lal A, Yang X
and Gorospe M: Identification of a target RNA motif for RNA-binding
protein HuR. Proc Natl Acad Sci USA. 101:2987–2992. 2004.PubMed/NCBI
|
|
24
|
Song NY and Surh YJ: Janus-faced role of
SIRT1 in tumorigenesis. Ann NY Acad Sci. 1271:10–19. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bosch-Presegue L and Vaquero A: The dual
role of sirtuins in cancer. Genes Cancer. 2:648–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan J, Luo K, Liu T and Lou Z: Regulation
of SIRT1 activity by genotoxic stress. Genes Dev. 26:791–796. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwon HS, Lim HW, Wu J, Schnolzer M, Verdin
E and Ott M: Three novel acetylation sites in the Foxp3
transcription factor regulate the suppressive activity of
regulatory T cells. J Immunol. 188:2712–2721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bollag G, Tsai J, Zhang J, et al:
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat
Rev Drug Discov. 11:873–886. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Turajlic S, Ali Z, Yousaf N and Larkin J:
Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opin
Investig Drugs. 22:739–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brilli L and Pacini F: Targeted therapy in
refractory thyroid cancer: current achievements and limitations.
Future Oncol. 7:657–668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Poulikakos PI, Persaud Y, Janakiraman M,
et al: RAF inhibitor resistance is mediated by dimerization of
aberrantly spliced BRAF(V600E). Nature. 480:387–390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Montagut C, Sharma SV, Shioda T, et al:
Elevated CRAF as a potential mechanism of acquired resistance to
BRAF inhibition in melanoma. Cancer Res. 68:4853–4861. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Greger JG, Eastman SD, Zhang V, et al:
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome
acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib,
mediated by NRAS or MEK mutations. Mol Cancer Ther. 11:909–920.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johannessen CM, Boehm JS, Kim SY, et al:
COT drives resistance to RAF inhibition through MAP kinase pathway
reactivation. Nature. 468:968–972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su F, Bradley WD, Wang Q, et al:
Resistance to selective BRAF inhibition can be mediated by modest
upstream pathway activation. Cancer Res. 72:969–978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nazarian R, Shi H, Wang Q, et al:
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
N-RAS upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Atefi M, von Euw E, Attar N, et al:
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
co-targeting the AKT/mTOR pathway. PLoS One. 6:e289732011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sanchez-Hernandez I, Baquero P, Calleros L
and Chiloeches A: Dual inhibition of (V600E)BRAF and the
PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma
cells through a MEK-independent mechanism. Cancer Lett.
314:244–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vergani E, Vallacchi V, Frigerio S, et al:
Identification of MET and SRC activation in melanoma cell lines
showing primary resistance to PLX4032. Neoplasia. 13:1132–1142.
2011.PubMed/NCBI
|
|
41
|
Lee MH, Lee SE, Kim DW, et al:
Mitochondrial localization and regulation of BRAFV600E in thyroid
cancer: a clinically used RAF inhibitor is unable to block the
mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab.
96:E19–E30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee SE, Lee JU, Lee MH, et al: RAF kinase
inhibitor-independent constitutive activation of Yes-associated
protein 1 promotes tumor progression in thyroid cancer.
Oncogenesis. 2:e552013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Uhlen M, Oksvold P, Fagerberg L, et al:
Towards a knowledge-based Human Protein Atlas. Nat Biotechnol.
28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zuo S, Liu C, Wang J, et al: IGFBP-rP1
induces p21 expression through a p53-independent pathway, leading
to cellular senescence of MCF-7 breast cancer cells. J Cancer Res
Clin Oncol. 138:1045–1055. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Warfel NA and El-Deiry WS:
p21WAF1 and tumourigenesis: 20 years after. Curr Opin
Oncol. 25:52–58. 2013.PubMed/NCBI
|
|
46
|
Deng C, Zhang P, Harper JW, Elledge SJ and
Leder P: Mice lacking p21CIP1/WAF1 undergo normal
development, but are defective in G1 checkpoint control. Cell.
82:675–684. 1995.
|
|
47
|
Gartel AL and Tyner AL: Transcriptional
regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 246:280–289.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
van Loosdregt J, Brunen D, Fleskens V,
Pals CE, Lam EW and Coffer PJ: Rapid temporal control of Foxp3
protein degradation by sirtuin-1. PLoS One. 6:e190472011.PubMed/NCBI
|
